Piper Sandler upgrades Neogen stock rating on turnaround progress

Neogen (NEOG) delivered a better-than-expected fiscal Q4 with adjusted EPS of $0.09 vs $0.05 consensus and revenue of $225.3M vs $212.52M, alongside core growth of 4.3% and food safety sales +5.8% (core). Piper Sandler upgraded NEOG to Overweight from Neutral and raised its price target to $14.00 from $13.00, citing improving adjusted EBITDA margins, positive free cash flow, restored product availability, and a completed manufacturing transition. Despite strong momentum (shares +67% YTD; +107% over 1 year) and analysts forecasting profitability this year, InvestingPro notes potential overvaluation vs fair value.

Analysis

NEOG is becoming a cleaner execution story, but the market is likely underpricing how much of the “turnaround” is now in the numbers. The key mechanism is not top-line acceleration; it is margin repair from better fill rates, less discounting, and lower operational friction as manufacturing normalizes. That supports near-term multiple expansion, but at 67% YTD the stock is already discounting a fairly optimistic path, so incremental upside now depends on sustained FCF conversion rather than another quarter of merely beating estimates.

The second-order winner is the broader food-safety consumables ecosystem: better product availability tends to restore share with distributors and reduces the risk that customers permanently re-source to incumbents or private-label alternatives. The loser is anyone who assumed the transition would create a durable share loss for NEOG; if service levels remain stable, that bear case weakens. The bigger competitive implication is pricing discipline: if NEOG can hold gross margin while rebuilding growth, smaller rivals without the same scale will feel it first.

The main risk is that consensus is extrapolating a stabilization phase into a sustainable growth regime too early. If the next 1-2 quarters show any wobble in core growth, margin cadence, or working capital release, the stock can de-rate quickly because this is still a credibility trade, not a secular growth compounder. Over 6-18 months, the thesis is falsified if management cannot sustain low-to-mid single-digit core growth while converting EBITDA into cash; that would suggest the new baseline is weaker than the market is pricing.

Key Decisions for Investors

• Do not chase NEOG after the upgrade; use strength to trim existing longs or wait for a pullback toward the low-$11s before adding. Risk/reward is now asymmetrical only if execution keeps surprising upward.
• If initiating new exposure, prefer a small starter long in NEOG with a hard risk limit below the prior breakout zone around $10.50. A close below that level would signal the market is no longer buying the turnaround narrative.
• For event risk into the next earnings print, consider a modest put hedge rather than outright shorting if already long; the setup is vulnerable to any margin or working-capital disappointment despite the bullish tone.
• Watch for confirmation in the next 1-2 quarters on core growth and free cash flow conversion. If either stalls, fade the upgrade-driven rerate and look for a 10-15% drawdown as the market resets the multiple.